Literature DB >> 28790294

[Nutrient Assessment and Perioperative Management in Esophageal Cancer Patients Undergoing Esophagectomy].

Makoto Sohda1, Hiroyuki Kuwano.   

Abstract

Esophagectomy is a most invasive operation, as compared with other operations of the gastrointestinal tract. Obstructions of the food passageway and the overgrowth of tissue postoperatively may lead to malnutrition. Therefore, significant assessment and management of nutrients is very important for esophageal cancer patients. The body mass index, albumin, the prognostic nutritional index, controlling nutritional status, and the Glasgow Prognostic Score are reported as useful assessment tools for esophageal cancer. The patient's general condition, including his or her nutritional status, influences the performance of esophagectomy. Therefore, improving the nutritional status enables an adaptation of therapy and leads to preventive benefits for decreasing postoperative complications. The previously cited nutritional tools are very useful indices because the measurement of each factor is convenient and fast. Also, early recovery from operative stress is the most important target of postoperative management after esophagectomy. Accurate and adequate perioperative management allows early recovery from operative stress in esophageal cancer patients. Preoperative steroid injection, oral care, respiratory training and rehabilitation, smoking cessation, and so on are very important for esophageal cancer patients. The efforts of a team that includes doctors, nurses, and healthcare providers are necessary for sufficient postoperative management after esophagectomy.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28790294

Source DB:  PubMed          Journal:  Kyobu Geka        ISSN: 0021-5252


  1 in total

1.  Impact Exerted by Nutritional Risk Screening on Clinical Outcome of Patients with Esophageal Cancer.

Authors:  Rui Wang; Hongfei Cai; Yang Li; Caiwen Chen; Youbin Cui
Journal:  Biomed Res Int       Date:  2018-03-27       Impact factor: 3.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.